BID and pancreatic neoplasm: The results showed that only the nonpolar extracts had antitumor activity, with an IC50 ranging between 30.91 and 39.12 μg/mL in the three pancreatic tumor lines tested (AsPC1, BxPC3 and SW1990) This extract showed synergistic action in combination with gemcitabine, increasing the expression of proapoptotic proteins (BAX and BID) and decreasing the expression of antiapoptotic proteins (BCL-2, XIAP, CIAP-2) [33].